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Introduction
Omalizumab is a monoclonal antibody approved for
the treatment of severe allergic asthma for patineis
above 6 years old in Europe, but its use has been
described successfully in other IgE-mediated diseases.
Objective
Evaluation of clinical response and safety of treatment
with omalizumab in a pediatric population.
Methods
Retrospective analysis of clinical data of pts aged <18 years
at the time of initiation of treatment with omalizumab in
our department from December 2009 to July 2013.
We evaluate adverse reactions, clinical outcome, reduction
or discontinuation of therapy according to allergic disease.
Results
Ten pts were proposed to omalizumab: 8M, 2F with a
mean age of 12.9 years ±3.9 [7-17]. All had bronchial
asthma: 3severe allergic asthma, 5severe atopic eczema
(AE), 1severe ocular allergy (OA) with risk for injury to
the cornea by conjunctival edema and 1 cow’s milk protein
allergy (CMA) with anaphylaxis during the protocol for
oral tolerance induction (OTI).
The mean duration of therapy with omalizumab was
12.3±13.35 months. The median serum total IgE l before
treatment was 991.5kU/L.
The average values of Asthma Control Test (ACT)
before and after omalizumab were 17 [15-24]. The mean
Scoring Atopic Dermatitis (SCORAD) before and after
omalizumab was 2 [34-90] and 24 [13-35].
The pts with EA, 1 was treated with cyclosporine, 1
azathioprine, 2 with systemic corticosteroids (SC). After
an average of 2 months of treatment there was a reduction
of azathioprine and after an average of 5.3 months suspen-
sion of SC and cyclosporine.
Two pts that had suspended Specific immunotherapy
(SI) for clinical worsening before omalizumab re-started
SI without occurrence of adverse reactions.
There were no adverse reactions to omalizumab.
Discussion
In our pediatric population, omalizumab shown to be
effective and safe in patients with severe uncontrolled
allergic disease, not only on asthma but also in other
pathologies, allowing application of other effective
therapeutics such as induction of food intolerance and
SI that can change the course of the disease. Although
more studies are still needed but this antibody appears
to have a promising role.
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